Zobrazeno 1 - 10 of 23 pro vyhledávání: '"Sandor Schokker"'
1
Akademický článek
A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)
Autor: Charlotte I Stroes, Sandor Schokker, Mohammed Khurshed, Stephanie O van der Woude, Ron AA Mathôt, Marije Slingerland, Judith de Vos-Geelen, Massimo Zucchetti, Cristina Matteo, Erik van Dijk, Bauke Ylstra, Victor Thijssen, Sarah Derks, Tesfay Godefa, Willemieke Dijksterhuis, Gerben E Breimer, Otto M van Delden, Rob HA Verhoeven, Sybren L Meijer, Maarten F Bijlsma, Hanneke WM van Laarhoven
Publikováno v: Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Purpose: Regorafenib monotherapy, a multikinase inhibitor of angiogenesis, tumor microenvironment, and tumorigenesis, showed promising results in gastric cancer. We aimed to assess the tolerability of regorafenib and paclitaxel in patients with advan
Externí odkaz: https://doaj.org/article/aed72a810b8b46b7a7487a5ebbe32545
Zobrazit plný text záznamu
2
Akademický článek
Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab
Autor: Sandor Schokker, Fabrizia Fusetti, Francesco Bonardi, Remco J. Molenaar, Ron A.A. Mathôt, Hanneke W.M. van Laarhoven
Publikováno v: mAbs, Vol 12, Iss 1 (2020)
Given the increasing use of combination therapy with multiple monoclonal antibodies (mAbs), there is a clinical need for multiplexing assays. For the frequently co-administered anti-human epidermal growth factor receptor 2 (HER2) mAbs trastuzumab and
Externí odkaz: https://doaj.org/article/d876719ce9404867ac2c605abf6f6503
Zobrazit plný text záznamu
6
Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer
Autor: Merel J. M. van Velzen, Aafke Creemers, Tom van den Ende, Sandor Schokker, Sarah Krausz, Roy J. Reinten, Frederike Dijk, Carel J. M. van Noesel, Hans Halfwerk, Sybren L. Meijer, Banafsche Mearadji, Sarah Derks, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven
Publikováno v: Gastric Cancer, 25(5), 906-915. Springer Japan
Gastric cancer, 25(5), 906-915. Springer Japan
van Velzen, M J M, Creemers, A, van den Ende, T, Schokker, S, Krausz, S, Reinten, R J, Dijk, F, van Noesel, C J M, Halfwerk, H, Meijer, S L, Mearadji, B, Derks, S, Bijlsma, M F & van Laarhoven, H W M 2022, ' Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer ', Gastric Cancer, vol. 25, no. 5, pp. 906-915 . https://doi.org/10.1007/s10120-022-01313-w
Background Circulating tumor DNA (ctDNA) has predictive and prognostic value in localized and metastatic cancer. This study analyzed the prognostic value of baseline and on-treatment ctDNA in metastatic gastroesophageal cancer (mGEC) using a region-s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8038e945df74cd91dcb8582cd8f9adb
https://research.vumc.nl/en/publications/93a91a4c-7e66-4063-83b6-1a320b9aaa59
Zobrazit plný text záznamu
7
Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma
Autor: Richard van Hillegersberg, Tom van den Ende, Sybren L. Meijer, Rob H.A. Verhoeven, Max Nieuwdorp, Mark P. G. Dings, Nadia Haj Mohammad, Tanja D. de Gruijl, Nicolien C. de Clercq, H.W.M. van Laarhoven, Jacques J. Bergman, Elisabeth D. Geijsen, Stella Mook, Sandor Schokker, Maarten C.C.M. Hulshof, Nicole C.T. van Grieken, Maarten F. Bijlsma, Bauke Ylstra, Jelle P. Ruurda, Mark I. van Berge Henegouwen, Suzanne S. Gisbertz, Tanya T.D. Soeratram
Publikováno v: van den Ende, T, Clercq, N D, van Berge Henegouwen, M I, Gisbertz, S S, Geijsen, D, Verhoeven, R, Meijer, S L, Schokker, S, Dings, M, Bergman, J J G H M, Haj Mohammad, N, Ruurda, J P, van Hillegersberg, R, Mook, S, Nieuwdorp, M, de Gruijl, T D, Soeratram, T T D, Ylstra, B, van Grieken, N C T, Bijlsma, M F, Hulshof, M C C M & van Laarhoven, H W 2021, ' Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma : A Single Arm Phase II Feasibility Trial (PERFECT) ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 27, no. 12, pp. 3351-3359 . https://doi.org/10.1158/1078-0432.CCR-20-4443
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clinical cancer research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clin Cancer Res
Purpose: The CROSS trial established neoadjuvant chemoradiotherapy (nCRT) for patients with resectable esophageal adenocarcinoma (rEAC). In the PERFECT trial, we investigated the feasibility and efficacy of nCRT combined with programmed-death ligand-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::014895e67130be48ac8dc681c6a1b2b3
http://www.scopus.com/inward/record.url?scp=85106021321&partnerID=8YFLogxK
Zobrazit plný text záznamu
8
A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX
Autor: Gerrit K. J. Hooijer, Sandor Schokker, Maarten C.C.M. Hulshof, Sybren L. Meijer, Charlotte I. Stroes, Stephanie O. van der Woude, Nadia Haj Mohammad, Cecile Grootscholten, Remco J. Molenaar, Mark I. van Berge Henegouwen, Jelle P Ruurda, Hanneke W. M. van Laarhoven, Ron A. A. Mathôt, Geert-Jan Creemers, Grard A. P. Nieuwenhuijzen, Rob H.A. Verhoeven, Johanna W. van Sandick, Annemieke Cats, Maarten F. Bijlsma, João P. Belo Pereira
Publikováno v: Cancers
Volume 13
Issue 4
Cancers, Vol 13, Iss 839, p 839 (2021)
Cancers, 13(4):839, 1-15. Multidisciplinary Digital Publishing Institute (MDPI)
Stroes, C I, Schokker, S, Molenaar, R J, Mathôt, R A A, Bijlsma, M F, van der Woude, S O, Pereira, J P B, Hooijer, G K J, Verhoeven, R H A, Cats, A, Grootscholten, C, van Sandick, J W, Creemers, G-J, Nieuwenhuijzen, G A P, Mohammad, N H, Ruurda, J P, Meijer, S L, Hulshof, M C C M, Henegouwen, M I V B & van Laarhoven, H W M 2021, ' A phase ii study demonstrates no feasibility of adjuvant treatment with six cycles of s-1 and oxaliplatin in resectable esophageal adenocarcinoma, with ercc1 as biomarker for response to sox ', Cancers, vol. 13, no. 4, 839, pp. 1-15 . https://doi.org/10.3390/cancers13040839
We assessed the feasibility of adjuvant S-1 and oxaliplatin following neoadjuvant chemoradiotherapy (nCRT) and esophagectomy. Patients treated with nCRT (paclitaxel, carboplatin) and esophagectomy received six 21-day cycles with oxaliplatin (130 mg/m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb8e328830eae98cc8a39b7e0ec77397
Zobrazit plný text záznamu
9
Phase II feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma: Trap study
Autor: Stephanie O. van der Woude, Roel J. Bennink, Ron A. A. Mathôt, Mark I. van Berge Henegouwen, Geke A. P. Hospers, Charlotte I. Stroes, Martijn G.H. van Oijen, Maurice J.C. van der Sangen, Maartje Los, Geert Jan Creemers, Annemieke Cats, Maarten F. Bijlsma, Sandor Schokker, Maarten C.C.M. Hulshof, Sybren L. Meijer, Hanneke W. M. van Laarhoven, Kausilia K. Krishnadath, Rob H.A. Verhoeven, Remco J. Molenaar, Grard A. P. Nieuwenhuijzen, Laurens V. Beerepoot, Cornelis J. A. Punt, Joos Heisterkamp, Marije Slingerland, Aafke Creemers
Publikováno v: Journal of Clinical Oncology, 38(5), 462-471. American Society of Clinical Oncology
Journal of clinical oncology, 38(5), 462-471. American Society of Clinical Oncology
Stroes, C I, Schokker, S, Creemers, A, Molenaar, R J, Hulshof, M C C M, van der Woude, S O, Bennink, R J, Mathôt, R A A, Krishnadath, K K, Punt, C J A, Verhoeven, R H A, van Oijen, M G H, Creemers, G J, Nieuwenhuijzen, G A P, van der Sangen, M J C, Beerepoot, L V, Heisterkamp, J, Los, M, Slingerland, M, Cats, A, Hospers, G A P, Bijlsma, M F, van Berge Henegouwen, M I, Meijer, S L & van Laarhoven, H W M 2020, ' Phase II feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma : Trap study ', Journal of Clinical Oncology, vol. 38, no. 5, pp. 462-471 . https://doi.org/10.1200/JCO.19.01814
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(5):JCO1901814, 462-471. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(5), 462-471. AMER SOC CLINICAL ONCOLOGY
J Clin Oncol
PURPOSE Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth factor receptor 2 (HER2) positive. Because dual-agent HER2 blockade demonstrated a survival benefit in breast cancer, we conducted a phase II feasibility
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22c9cfd388de41f0f13b5f3e8fd2b40e
https://research.vumc.nl/en/publications/4716be5e-05fb-49a2-9bc2-37c922f3ff70
Zobrazit plný text záznamu
10
Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab
Autor: Fabrizia Fusetti, Ron A. A. Mathôt, Francesco Bonardi, Sandor Schokker, Hanneke W. M. van Laarhoven, Remco J. Molenaar
Publikováno v: mAbs
article-version (VoR) Version of Record
mAbs, 12(1):1795492. Landes Bioscience
Given the increasing use of combination therapy with multiple monoclonal antibodies (mAbs), there is a clinical need for multiplexing assays. For the frequently co-administered anti-human epidermal growth factor receptor 2 (HER2) mAbs trastuzumab and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f86cffbaba4b098218c8689408aae3
http://www.scopus.com/inward/record.url?scp=85088908981&partnerID=8YFLogxK
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje